Search

Your search keyword '"Wallace, Danielle S."' showing total 12 results
Start Over Author "Wallace, Danielle S."
12 results on '"Wallace, Danielle S."'

6. First dose infusion reaction during anti-CD20 monoclonal antibody therapy in chronic lymphocytic leukemia associates with high IP-10 levels amid cytokine release syndrome

Author

Chu, Charles C, primary, Moore, Jeremiah E., additional, Bloom, Paige C., additional, Bruno, Jennifer E., additional, Quataert, Sally A., additional, Mosmann, Tim R., additional, Jaimes-Delgadillo, Nydia, additional, Herne, Christine Ann, additional, VanDerMeid, Karl R., additional, Baran, Andrea M., additional, Peterson, Derick R., additional, Taylor, Ronald P, additional, Elliott, Michael Rusty, additional, Wallace, Danielle S., additional, Barr, Paul M., additional, and Zent, Clive S., additional

Published
2023
Full Text
View/download PDF

7. ALK‐rearranged CD30‐positive poorly differentiated lung adenocarcinoma, mimicking anaplastic large‐cell lymphoma.

Author

George, Giby V, Wallace, Danielle S, Wang, Ying, Carney, John, Elsadawi, Murad, Burack, W Richard, Evans, Andrew G, Barr, Paul M, Velez, Moises J, and El Hussein, Siba

Subjects
*ANAPLASTIC large-cell lymphoma, *CAUDA equina syndrome
Abstract

This article discusses a case of a 64-year-old man who presented with back pain and cough. Imaging revealed masses in the chest and abdomen, as well as pleural effusions. Pathological examination of the tissue revealed a poorly differentiated malignant neoplasm that initially appeared to be anaplastic large-cell lymphoma (ALCL) based on immunohistochemical staining. However, further molecular testing confirmed a diagnosis of ALK-rearranged lung adenocarcinoma. The patient has responded to ALK-inhibitor therapy. The article emphasizes the importance of careful interpretation of immunohistochemical stains in cases of poorly differentiated ALK+/CD30+ neoplasms. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed/refractory mantle cell lymphoma.

Author

Wallace, Danielle S., Rowland, Chris, Hill, Brian T., Baran, Andrea M., Casulo, Carla, Reagan, Patrick M., Winter, Allison, Karmali, Reem, Winter, Jane N., Gordon, Leo I., Bui, Andrew, Sportelli, Peter, Miskin, Hari P., Weiss, Michael S., Friedberg, Jonathan W., Ma, Shuo, and Barr, Paul M.

Subjects
*BRUTON tyrosine kinase, *VENETOCLAX, *MANTLE cell lymphoma
Abstract

Patients with mantle cell lymphoma require treatment options following BTK inhibition, as evidenced by the 14.6 months median OS rate from initiation of BTK inhibitor in the recently published SCHOLAR-2 analysis [[11]]. Nine patients were refractory to prior therapy, 9 had previously received a BTK inhibitor (BTKi) including 7 who were refractory to BTKi and there were 3 who had progressive lymphoma following chimeric antigen receptor T-cell (CAR-T) therapy. Novel agents such as the Bruton's tyrosine kinase (BTK) inhibitors have improved outcomes for patients with mantle cell lymphoma (MCL) and continue to change treatment paradigms [[1]]. [Extracted from the article]

Published
2023
Full Text
View/download PDF

9. Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Author

Zent, Clive S., primary, Moore, Jeremiah E., additional, Bloom, Paige C., additional, Chu, Charles C., additional, Bruno, Jennifer E., additional, Herne, Christine A., additional, Baran, Andrea M, additional, Quataert, Sally A., additional, Mosmann, Tim R., additional, Taylor, Ronald P., additional, Wallace, Danielle S., additional, Elliott, Michael R., additional, and Barr, Paul M., additional

Published
2022
Full Text
View/download PDF

11. Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Author

Wallace, Danielle S., primary, Baran, Andrea M., additional, Friedberg, Jonathan W., additional, Reagan, Patrick M., additional, Casulo, Carla, additional, Friend, Mijamin, additional, Williams, Alyssa R., additional, Dakin, Peter D, additional, Zent, Clive S., additional, and Barr, Paul M., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results